- $36.58bn
- $40.42bn
- $10.40bn
Alcon AG reports results for the quarter ended September 30 - Earnings Summary
Alcon shares fall as tighter eye-care market outlook raises growth concerns (updated)
Alcon seen down after sales miss, tighter outlook
Swiss stocks - Factors to watch on November 11
Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth
Alcon AG expected to post earnings of 87 cents a share - Earnings Preview
Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Swiss stocks - Factors to watch on October 19
Brief: FDA Approves Alcon’S BRYTL Eye Drops
Advisory: Alert incorrectly tagged to Omega Interactive Technologies withdrawn
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Alcon AG Prices EUR 500 Million 3.875% Senior Notes Due 2033
Swiss stocks - Factors to watch on August 12
European stocks pause near record highs as earnings optimism offsets energy supply concerns
Brief: Alcon CFO On Call - Higher Gross Margin In Q3 Due To Tariff Refunds
European stocks pause near record highs as oil rally keeps investors cautious
Eye care company Alcon raises margin outlook, shares jump (updated)